Princess Alexandra Hospital

Running trials

• Not yet recruiting

  Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma

  NCT07634289· Phase 2· Olivia Newton-John Cancer Research Institute· Source

• Not yet recruiting

  OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma

  NCT07739017· Phase 1· Olivia Newton-John Cancer Research Institute· Source

• Recruiting

  Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

  NCT07804186· Phase 3· IDEAYA Biosciences· Source

• Recruiting

  The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma

  NCT07565285· Phase 2· Primmune Therapeutics, Inc.· Source

• Recruiting

  A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  NCT07554339· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07562152· Phase 3· Immuneering Corporation· Source

• Recruiting

  A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

  NCT07513376· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

  NCT07431827· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

  NCT07277231· Phase 3· BeOne Medicines· Source

• Recruiting

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  NCT07063745· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07225946· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Feasibility Study Implant of the WiSE® CRT System With an Intracardiac Pacemaker to Achieve Totally Leadless CRT

  NCT06561932· EBR Systems, Inc.· Source

• Recruiting

  A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

  NCT07221474· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  NCT07213674· Phase 3· Amgen· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  PRIORITY-CONNECT 2 Trial

  NCT06976710· Surgical Outcomes Research Centre (SOuRCe)· Source

• Recruiting

  A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

  NCT07149857· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma

  NCT07138222· Peter MacCallum Cancer Centre, Australia· Source

• Recruiting

  A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

  NCT06855771· Phase 2· Bristol-Myers Squibb· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Pfizer· Source

• Recruiting

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· Phase 3· Pfizer· Source

• Active, not recruiting

  BIO|CONCEPT.CorSky, First in Human Study for the CorSky ICD Family

  NCT06840509· Biotronik Australia Pty Ltd.· Source

• Recruiting

  Hypoglossal Nerve Stimulation for the Treatment of Adult Obstructive Sleep Apnea

  NCT07049744· XII Medical· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

  NCT06944522· Phase 3· BlueRock Therapeutics· Source

• Recruiting

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· Phase 3· BeOne Medicines· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

  NCT06563895· Phase 3· Eidos Therapeutics, a BridgeBio company· Source

• Recruiting

  A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06935357· Phase 3· Biogen· Source

• Recruiting

  A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  NCT06875310· Phase 3· Mirati Therapeutics Inc.· Source

• Active, not recruiting

  ASCEND CSP IDE Study

  NCT06830746· Abbott Medical Devices· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819878· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma

  NCT06767306· Phase 2· Melanoma Institute Australia· Source

• Recruiting

  Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

  NCT06841055· Phase 2· BioNTech SE· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

  NCT06780137· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  NCT06909825· Phase 2· Fusion Pharmaceuticals Inc.· Source

• Recruiting

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease

  NCT06732180· Phase 1· Gain Therapeutics, Inc.· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

  NCT06618287· Phase 1/2· Bristol-Myers Squibb· Source

• Recruiting

  Implementing Surgery School Prehabilitation Using Telehealth

  NCT06631872· University of Melbourne· Source

• Recruiting

  A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

  NCT06284317· Phase 3· ETOP IBCSG Partners Foundation· Source

• Active, not recruiting

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Phase 3· Pfizer· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  NCT06588478· Phase 2· Loxo Oncology, Inc.· Source

• Recruiting

  Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

  NCT06585410· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

  NCT06691984· Phase 3· Amgen· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

  NCT06492837· Phase 2· Fondazione Italiana Linfomi - ETS· Source

• Recruiting

  A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  NCT06623422· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

  NCT06441747· Phase 2· Australasian Gastro-Intestinal Trials Group· Source

Showing 50 of 168.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer19 recruiting
• Melanoma11 recruiting
• Prostate cancer9 recruiting
• Amyloidosis5 recruiting
• Chronic lymphocytic leukaemia5 recruiting
• Colorectal cancer5 recruiting
• Head and neck cancer5 recruiting
• Liver and biliary tract cancer5 recruiting
• Pancreatic cancer4 recruiting
• Parkinson disease4 recruiting
• Heart failure3 recruiting
• Kidney cancer3 recruiting
• Stroke3 recruiting
• Triple-negative breast cancer3 recruiting
• Bladder cancer2 recruiting
• Cervical cancer2 recruiting
• Childhood cancers2 recruiting
• Crohn's disease2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Multiple myeloma2 recruiting
• Ovarian cancer2 recruiting
• Sarcoma2 recruiting
• Acute myeloid leukaemia1 recruiting
• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Dystonia1 recruiting
• Endometrial cancer1 recruiting
• Essential tremor1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Follicular lymphoma1 recruiting
• Glioblastoma1 recruiting
• High blood pressure1 recruiting
• IgA nephropathy1 recruiting
• Mantle cell lymphoma1 recruiting
• Myasthenia gravis1 recruiting
• Obstructive sleep apnoea1 recruiting
• Primary biliary cholangitis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Recruiting

  Study Evaluating the Efficacy and Safety of Artesunate

  NCT06853184· Phase 2· Amivas Inc.· Source

• Terminated

  A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

  NCT06256484· Phase 1· Atara Biotherapeutics· Source

• Completed

  Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT06058793· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  NCT05920356· Phase 3· Amgen· Source

• Completed

  A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old

  NCT06064929· Phase 1· HI-Bio, A Biogen Company· Source

• Completed

  SBD121, a Synbiotic Medical Food for RA Management

  NCT06005220· Solarea Bio, Inc· Source

• Terminated

  The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

  NCT04876651· Phase 3· Telix Pharmaceuticals (Innovations) Pty Ltd· Source

• Completed

  IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

  NCT05989711· Phase 2· Altimmune, Inc.· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Amgen· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer

  NCT05505825· Phase 1/2· Akeso· Source

• Completed

  A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma

  NCT05419388· Phase 2· Hoffmann-La Roche· Source

• Completed

  Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

  NCT04530123· Phase 2· Takeda· Source

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase)

  NCT05203224· Phase 2· University of Melbourne· Source

• Terminated

  Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

  NCT04958785· Phase 2· Gilead Sciences· Source

• Completed

  Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis

  NCT05199337· Phase 1/2· K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.· Source

• Terminated

  The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

  NCT04985968· Phase 3· InDex Pharmaceuticals· Source

• Completed

  Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

  NCT04987203· Phase 3· AVEO Pharmaceuticals, Inc.· Source

• Terminated

  Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

  NCT04854499· Phase 2· Gilead Sciences· Source

• Completed

  SER150 vs Placebo in Diabetic Kidney Disease

  NCT04881123· Phase 2/3· Serodus AS· Source

• Terminated

  Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

  NCT04778397· Phase 3· Gilead Sciences· Source

• Completed

  Optimal Post Tpa-Iv Monitoring in Ischemic Stroke

  NCT03734640· Craig Anderson· Source

• Completed

  Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

  NCT04644237· Phase 2· Daiichi Sankyo· Source

• Completed

  Comprehensive Geriatric Assessment for Frail Older People With Chronic Kidney Disease - The GOAL Trial

  NCT04538157· The University of Queensland· Source

• Completed

  DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

  NCT04334759· Phase 3· PrECOG, LLC.· Source

• Terminated

  IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)

  NCT04524949· Phase 2· Imcyse SA· Source

• Completed

  The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

  NCT04338399· Phase 3· Adlai Nortye Biopharma Co., Ltd.· Source

• Completed

  Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - a Sustained, Low Dose Dexamethasone Therapy

  NCT04576689· Phase 2· Ripple Therapeutics Pty Ltd· Source

• Completed

  A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

  NCT04543617· Phase 3· Hoffmann-La Roche· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Terminated

  Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients with Large Vessel Occlusion

  NCT04454788· Phase 3· University of Melbourne· Source

• Terminated

  Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial

  NCT04316013· Phase 3· Peter MacCallum Cancer Centre, Australia· Source

• Completed

  Preventing Adverse Cardiac Events in COPD

  NCT03917914· Phase 3· The George Institute· Source

• Completed

  Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

  NCT04303780· Phase 3· Amgen· Source

• Completed

  A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

  NCT04102020· Phase 3· AbbVie· Source

• Completed

  CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

  NCT04136171· Phase 3· Ionis Pharmaceuticals, Inc.· Source

• Completed

  A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

  NCT04294810· Phase 3· Hoffmann-La Roche· Source

• Completed

  Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

  NCT04248829· Phase 3· Yuhan Corporation· Source

• Completed

  Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

  NCT04215978· Phase 1· BeiGene· Source

• Completed

  TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

  NCT04129502· Phase 3· Takeda· Source

• Recruiting

  Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

  NCT03573089· The University of Queensland· Source

• Completed

  A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases

  NCT03497767· Phase 2· Trans Tasman Radiation Oncology Group· Source

• Completed

  Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

  NCT03976375· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

  NCT03626688· Phase 3· United Therapeutics· Source

• Completed

  A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

  NCT03734016· Phase 3· BeiGene· Source

• Completed

  A Trial of Radiotherapy and Durvalumab in DLBCL and FL

  NCT03610061· Phase 1· Austin Health· Source

• Completed

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Phase 3· Eli Lilly and Company· Source

• Terminated

  Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

  NCT03616470· Phase 3· GlycoMimetics Incorporated· Source

• Completed

  DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

  NCT03529110· Phase 3· Daiichi Sankyo· Source

Showing 50 of 69.

Conditions

Diseases this institution publishes on or runs trials for.

• Melanoma41 works · 21 trials
• Head and neck cancer17 works · 10 trials
• Postural tachycardia syndrome (POTS)3 works · 0 trials